Base de dados : MEDLINE
Pesquisa : D02.886.640.074.249 [Categoria DeCS]
Referências encontradas : 2000 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 200 ir para página                         

  1 / 2000 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29328644
[Au] Autor:Grgov S; Tasic T; Radovanovic-Dinic B; Benedeto-Stojanov D
[Ti] Título:Can probiotics improve efficiency and safety profile of triple Helicobacter pylori eradication therapy? A prospective randomized study.
[So] Source:Vojnosanit Pregl;73(11):1044-9, 2016 Nov.
[Is] ISSN:0042-8450
[Cp] País de publicação:Serbia
[La] Idioma:eng
[Ab] Resumo:Background/Aim: Some studies suggest the benefit of applying different probiotic strains in combination with antibiotics in the eradication of Helicobacter pylori (H. pylori) infection. The aim of this study was to evaluate the effect of co-administration of multiple probiotic strains with triple H. pylori eradication therapy.This prospective study included 167 patients with dyspeptic symptoms and chronic gastritis who were diagnosed with H. pylori infection and randomized into two groups. The group I of 77 patients underwent triple eradication therapy, for 7 days, with lansoprazole, 2 × 30 mg half an hour before the meal, amoxicillin 2 × 1.000 mg per 12 hours and clarithromycin 2 × 500 mg per 12 hours. After the 7th day of the therapy, lansoprazole continued at a dose of 30 mg for half an hour before breakfast for 4 weeks. The group II of 90 patients received the same treatment as the patients of the group I, with the addition of the probiotic cultures in the form of a capsule comprising Lactobacillus Rosell-52, Lactobacillus Rosell-11, Bifidobacterium Rosell-1755 and Saccharomyces boulardii, since the beginning of eradication for 4 weeks. Eradication of H. pylori infection control was performed 8 weeks after the therapy by rapid urease test and histopathologic evaluation of endoscopic biopsies or by stool antigen test for H. pylori.Eradication of H. pylori infection was achieved in 93.3% of the patients who received probiotics with eradication therapy and in 81.8% of patients who were only on eradication therapy without probiotics. The difference in eradication success was statistically significant, (p < 0.05). The incidence of adverse effects of eradication therapy was higher in the group of patients who were not on probiotic (28.6%) than in the group that received probiotic (17.7%), but the difference was not statistically significant.Multiple probiotic strains addition to triple eradication therapy of H. pylori achieves a significantly better eradication success, with fewer side effects of antibiotics.
[Mh] Termos MeSH primário: Amoxicilina/uso terapêutico
Antibacterianos/uso terapêutico
Claritromicina/uso terapêutico
Gastrite/tratamento farmacológico
Infecções por Helicobacter/tratamento farmacológico
Helicobacter pylori/efeitos dos fármacos
Lansoprazol/uso terapêutico
Probióticos/uso terapêutico
Inibidores da Bomba de Prótons/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Amoxicilina/efeitos adversos
Antibacterianos/efeitos adversos
Biópsia
Doença Crônica
Claritromicina/efeitos adversos
Quimioterapia Combinada
Feminino
Gastrite/diagnóstico
Gastrite/microbiologia
Gastroscopia
Infecções por Helicobacter/diagnóstico
Infecções por Helicobacter/microbiologia
Helicobacter pylori/patogenicidade
Seres Humanos
Lansoprazol/efeitos adversos
Masculino
Meia-Idade
Probióticos/efeitos adversos
Estudos Prospectivos
Inibidores da Bomba de Prótons/efeitos adversos
Sérvia
Fatores de Tempo
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Proton Pump Inhibitors); 0K5C5T2QPG (Lansoprazole); 804826J2HU (Amoxicillin); H1250JIK0A (Clarithromycin)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180213
[Lr] Data última revisão:
180213
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180113
[St] Status:MEDLINE
[do] DOI:10.2298/VSP150415127G


  2 / 2000 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29223540
[Au] Autor:Luo C; Chen H; Wang Y; Lin G; Li C; Tan L; Su Z; Lai X; Xie J; Zeng H
[Ad] Endereço:Guangdong Provincial Key Laboratory of New Drug Development and Research of Chinese Medicine, Mathematical Engineering Academy of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou 510006, PR China.
[Ti] Título:Protective effect of coptisine free base on indomethacin-induced gastric ulcers in rats: Characterization of potential molecular mechanisms.
[So] Source:Life Sci;193:47-56, 2018 Jan 15.
[Is] ISSN:1879-0631
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:AIMS: The aim of this study was to comparatively investigate the potential gastroprotective effect and underlying mechanisms of coptisine free base (CFB, 8-hydroxy-7, 8-dihydrocoptisine), berberine and lansoprazole against indomethacin-induced gastric ulcer in rats. MATERIALS AND METHODS: CFB (10, 20 and 40mg/kg), berberine (20mg/kg) and lansoprazole (30mg/kg) were orally administrated to rats prior to indometacin ingestion, and gastric lesions were evaluated macroscopically and histologically, and further analyzed by ELISA, qRT-PCR and Western blot. KEY FINDINGS: CFB exerted comparable or superior gastroprotective effect to berberine in protecting against indomethacin-induced gastric injury. CFB pretreatment significantly enhanced the levels of superoxide dismutase (SOD) and glutathione (GSH), and markedly decreased the malonaldehyde (MDA) content. CFB administration effectively suppressed the levels of myeloperoxidase (MPO), interleukin-1ß (IL-1ß), tumor necrosis factor-α (TNF-α) and angiotensin II (Ang II). Besides, CFB substantially up-regulated the mRNA expressions of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), and promoted gastric mucosal prostaglandin E level (PGE ). Furthermore, CFB pretreatment remarkably increased the translocation of nuclear factor erythroid 2-related factor 2 (Nrf2) from cytosol into the nucleus, and the expression of heme oxygenase-1 (HO-1), while significantly decreased the expression of mitogen activated protein Kinase Kinase 6 (MKK6) and translocation of p38 mitogen-activated protein kinase (p38 MAPK). SIGNIFICANCE: This was the first investigation reporting the anti-ulcer effect of protoberberine alkaloid free base on in vivo rodent model. The gastroprotective mechanism of CFB might involve favorable regulation of antioxidant and anti-inflammatory status mediated, at least partially, by the Nrf2 signaling pathway and p38 MAPK translocation.
[Mh] Termos MeSH primário: Berberina/análogos & derivados
Úlcera Gástrica/tratamento farmacológico
[Mh] Termos MeSH secundário: Animais
Anti-Inflamatórios/farmacologia
Antioxidantes/farmacologia
Berberina/metabolismo
Berberina/farmacologia
Berberina/uso terapêutico
Ciclo-Oxigenase 1/metabolismo
Ciclo-Oxigenase 2/metabolismo
Modelos Animais de Doenças
Mucosa Gástrica/patologia
Indometacina
Interleucina-1beta/metabolismo
Lansoprazol/farmacologia
Lansoprazol/uso terapêutico
Masculino
Ratos
Úlcera Gástrica/patologia
Superóxido Dismutase/metabolismo
Fator de Necrose Tumoral alfa/metabolismo
Proteínas Quinases p38 Ativadas por Mitógeno/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents); 0 (Antioxidants); 0 (Interleukin-1beta); 0 (Tumor Necrosis Factor-alpha); 0GCL71VN14 (coptisine); 0I8Y3P32UF (Berberine); 0K5C5T2QPG (Lansoprazole); EC 1.14.99.1 (Cyclooxygenase 1); EC 1.14.99.1 (Cyclooxygenase 2); EC 1.15.1.1 (Superoxide Dismutase); EC 2.7.11.24 (p38 Mitogen-Activated Protein Kinases); XXE1CET956 (Indomethacin)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180108
[Lr] Data última revisão:
180108
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171211
[St] Status:MEDLINE


  3 / 2000 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28953640
[Au] Autor:Li MJ; Li Q; Sun M; Liu LQ
[Ad] Endereço:aSchool of Pharmacy, Shanxi Medical University bDepartment of Pharmacy, The First Hospital of Shanxi Medical University, Taiyuan cDepartment of Oncology, Zhongnan Hospital of Wuhan University, Hubei Key Laboratory of Tumor Biological Behaviors & Hubei Cancer Clinical Study Center, Wuhan dDepartment of General Surgery, Taihe Hospital, Hubei University of Medicine, Shiyan, P.R. China.
[Ti] Título:Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis.
[So] Source:Medicine (Baltimore);96(39):e8120, 2017 Sep.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: This study compared the effectiveness and acceptability of all Food and Drug Administration (FDA)-recommended dose proton pump inhibitors (PPIs) in erosive esophagitis (EE): Dexlansoprazole 60 mg, Esomeprazole 40 mg, Esomeprazole 20 mg, Pantoprazole 40 mg, Lansoprazole 30 mg, Rabeprazole 20 mg, Omeprazole 20 mg. METHODS: A systematic literature search was performed using PubMed, Embase, and Cochrane Library. Totally, 25 randomized controlled trials (RCTs) met study selection criteria and were incorporated in this network meta-analysis (NMA) study. RESULTS: For the NMA, eligible RCTs of adults with EE verified by endoscopic examination were randomly assigned to the licensed PPIs at least 4 weeks of continuous therapy. The primary efficacy outcome was the endoscopic healing rates at 4 and 8 weeks. Heartburn relief rates were a secondary efficacy outcome. The rates of withdrawal were analyzed as a safety outcome. In comparison to the common comparator omeprazole 20 mg, esomeprazole 40 mg provided significantly healing rates at 4 weeks [odds ratio (OR), 1.46 (95% confidence interval, 95% CI, 1.24-1.71)] and 8 weeks [1.58 (1.29-1.92)], and improved the heartburn relief rates [1.29 (1.07-1.56)]. In comparison to lansoprazole 30 mg, esomeprazole 40 mg provided significantly healing rates at 4 weeks [1.30 (1.10-1.53)] and 8 weeks [1.37 (1.13-1.67)], and improved the heartburn relief rates [1.29 (1.03-1.62)]. In terms of acceptability, only dexlansoprazole 60 mg had significantly more all-cause discontinuation than omeprazole 20 mg [1.54 (1.03-2.29)], pantoprazole 40 mg [1.68 (1.08-2.63)], and lansoprazole 30 mg [1.38 (1.02-1.88)]. CONCLUSION: The standard-dose esomeprazole 40 mg had more superiority in mucosal erosion healing and heartburn relief. Esomeprazole 40 mg, pantoprazole 40 mg, esomeprazole 20 mg, and lansoprazole 30 mg showed more benefits in effectiveness and acceptability than other interventions.
[Mh] Termos MeSH primário: Esofagite Péptica/tratamento farmacológico
Inibidores da Bomba de Prótons/administração & dosagem
[Mh] Termos MeSH secundário: 2-Piridinilmetilsulfinilbenzimidazóis/administração & dosagem
Adulto
Pesquisa Comparativa da Efetividade
Dexlansoprazol/administração & dosagem
Esomeprazol/administração & dosagem
Esofagite Péptica/complicações
Feminino
Azia/tratamento farmacológico
Azia/etiologia
Seres Humanos
Lansoprazol/administração & dosagem
Masculino
Meia-Idade
Metanálise em Rede
Omeprazol/administração & dosagem
Rabeprazol/administração & dosagem
Resultado do Tratamento
Estados Unidos
United States Food and Drug Administration
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS
[Nm] Nome de substância:
0 (2-Pyridinylmethylsulfinylbenzimidazoles); 0 (Proton Pump Inhibitors); 0K5C5T2QPG (Lansoprazole); 32828355LL (Rabeprazole); D8TST4O562 (pantoprazole); KG60484QX9 (Omeprazole); N3PA6559FT (Esomeprazole); UYE4T5I70X (Dexlansoprazole)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171013
[Lr] Data última revisão:
171013
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170928
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008120


  4 / 2000 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28412091
[Au] Autor:Khaleel SA; Alzokaky AA; Raslan NA; Alwakeel AI; Abd El-Aziz HG; Abd-Allah AR
[Ad] Endereço:Pharmacology and Toxicology Department, Faculty of Pharmacy (Girls), Al-Azhar University, Cairo, Egypt. Electronic address: sa7ar_22@yahoo.com.
[Ti] Título:Lansoprazole halts contrast induced nephropathy through activation of Nrf2 pathway in rats.
[So] Source:Chem Biol Interact;270:33-40, 2017 May 25.
[Is] ISSN:1872-7786
[Cp] País de publicação:Ireland
[La] Idioma:eng
[Ab] Resumo:Contrast-induced nephropathy (CIN) is an important cause of acute kidney injury characterized by significant mortality and morbidity. To date, there is no successful protective regimen for CIN especially in poor kidney function patients. Lansoprazole has been shown to exert antioxidant action through induction of nuclear factor-erythroid 2-related factor 2 (Nrf2) pathway. The aim of the present study is to investigate the potential of lansoprazole to activate Nrf2 pathway in the kidney and consequently to protect against oxidative stress induced by iodinated contrast media. Lansoprazole, at a dose of 100 mg/kg, showed a significant induction of Nrf2 mRNA after 3 h. Administration of contrast media induced significant increase in serum creatinine and blood urea nitrogen, histological deterioration, and reduction in total antioxidant capacity. Moreover, it instigated the defensive Nrf2 gene expression and immunoreactivity. In addition, there were overexpression of HO-1, caspase 3, p53 and IL6 genes and downregulation of Bcl2 gene. Pre-treatment with lansoprazole (100 mg/kg) ameliorated the nephrotoxicity parameters and oxidative stress, improved histological lesions, and hijacked apoptotic and inflammatory markers that were provoked by contrast media. In conclusion, lansoprazole attenuates experimental CIN which might be due to activation of Nrf2 antioxidant defence pathway. These findings highlight the potential benefit of incorporating lansoprazole in the protective regimen against CIN especially for susceptible patients.
[Mh] Termos MeSH primário: Heme Oxigenase-1/metabolismo
Rim/efeitos dos fármacos
Lansoprazol/farmacologia
Lansoprazol/uso terapêutico
Fator 2 Relacionado a NF-E2/efeitos dos fármacos
Nefrite/tratamento farmacológico
Transdução de Sinais/efeitos dos fármacos
[Mh] Termos MeSH secundário: Administração Oral
Animais
Meios de Contraste/toxicidade
Imunofluorescência
Rim/patologia
Masculino
Fator 2 Relacionado a NF-E2/genética
Fator 2 Relacionado a NF-E2/metabolismo
Nefrite/induzido quimicamente
Ratos
Ratos Wistar
Reação em Cadeia da Polimerase em Tempo Real
Regulação para Cima/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Contrast Media); 0 (NF-E2-Related Factor 2); 0K5C5T2QPG (Lansoprazole); EC 1.14.14.18 (Heme Oxygenase-1)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170524
[Lr] Data última revisão:
170524
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170417
[St] Status:MEDLINE


  5 / 2000 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28340819
[Au] Autor:Ciftci HS; Karadeniz MS; Tefik T; Caliskan Y; Yazici H; Demir E; Turkmen A; Nane I; Oguz FS; Aydin F
[Ad] Endereço:Department of Medical Biology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey. Electronic address: hayriyesenturk@gmail.com.
[Ti] Título:Influence of Proton Pump Inhibitors on Mycophenolic Acid Pharmacokinetics in Patients With Renal Transplantation and the Relationship With Cytochrome 2C19 Gene Polymorphism.
[So] Source:Transplant Proc;49(3):490-496, 2017 Apr.
[Is] ISSN:1873-2623
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Most patients have serious digestive complications after renal transplantation. Therefore, it is important to protect gastrointestinal function to improve the survival rate of transplant patients. Proton pump inhibitors (PPIs) such as lansoprazole and rabeprazole are widely administered to renal transplant patients with mycophenolic acid (MPA) in the perioperative period. PPIs are metabolized by cytochrome (CYP) 2C19 enzymes. Mycophenolate sodium (MYF) and mycophenolate mofetil (MMF) have been used in immunosuppression. Clinically relevant drug-drug interactions have been described between immunosuppressive drugs. In the present study, we investigated the drug interaction between MPA and lansoparazole or rabeprazole and the impact of CYP2C19 polymorphisms on these drug interactions after renal transplantation. MATERIALS AND METHODS: A total of 125 renal transplant patients taking MPA derivatives between 2012 and 2016 were included in this study. The 125 patients were divided into 6 groups: MMF/tacrolimus/steroid together with lansoprazole or rabeprazole; MYF/tacrolimus/steroid together with lansoprazole or rabeprazole and without PPI. The single nucleotide polymorphisms of CYP2C19 were determined by the polymerase chain reaction-restriction fragment length polymorphism. Plasma concentrations of MPA were measured by cloned enzyme donor immunoassay. Clinical parameters such as incidence of delayed graft function and acute rejection, the rate of change of serum creatinine, toxicity, and gastrointestinal adverse effects were analyzed retrospectively. RESULTS: The mean concentrations of MPA in the MYF group were higher than those in the MMF group. The mean dose-adjusted blood concentration of MPA coadministered with lansoprazole was lower than that of MPA with rabeprazole or without PPI in MMF and MYF groups (P < .05). In patients with the CYP2C19*2/*2 genotype, the mean concentrations of MMF with lansoprazole were significantly lower than those with rabeprazole with MMF or without PPI (P < .05). Gastrointestinal side effects were significantly higher in MMF with lansoprazole group than in MYF with lansoprazole group (P < .05). However, no differences were found according to genotype distribution in all groups (P > .05). CONCLUSION: Polymorphisms in CYP2C19 are related to the metabolic oxidation of drugs to varying degrees. Both genetic and clinical factors in pharmacokinetics may help to make further progress toward individualized therapy to yield maximum efficacy with minimal side effects.
[Mh] Termos MeSH primário: Citocromo P-450 CYP2C19/genética
Imunossupressores/farmacocinética
Transplante de Rim
Ácido Micofenólico/farmacocinética
Inibidores da Bomba de Prótons/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Interações Medicamentosas
Quimioterapia Combinada
Feminino
Genótipo
Seres Humanos
Imunossupressores/uso terapêutico
Lansoprazol/uso terapêutico
Masculino
Meia-Idade
Ácido Micofenólico/análogos & derivados
Ácido Micofenólico/uso terapêutico
Polimorfismo de Fragmento de Restrição
Polimorfismo de Nucleotídeo Único
Rabeprazol/uso terapêutico
Estudos Retrospectivos
Tacrolimo/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Immunosuppressive Agents); 0 (Proton Pump Inhibitors); 0K5C5T2QPG (Lansoprazole); 32828355LL (Rabeprazole); EC 1.14.14.1 (CYP2C19 protein, human); EC 1.14.14.1 (Cytochrome P-450 CYP2C19); HU9DX48N0T (Mycophenolic Acid); WM0HAQ4WNM (Tacrolimus)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170516
[Lr] Data última revisão:
170516
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170326
[St] Status:MEDLINE


  6 / 2000 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28139495
[Au] Autor:Hu ZH; Shi AM; Hu DM; Bao JJ
[Ad] Endereço:Department of Pharmacy, The Second Hospital Affiliated to Soochow University, Suzhou, People's Republic of China.
[Ti] Título:Efficacy of proton pump inhibitors for patients with duodenal ulcers: A pairwise and network meta-analysis of randomized controlled trials.
[So] Source:Saudi J Gastroenterol;23(1):11-19, 2017 Jan-Feb.
[Is] ISSN:1998-4049
[Cp] País de publicação:India
[La] Idioma:eng
[Ab] Resumo:BACKGROUND/AIM: To compare the efficacy and tolerance of different proton pump inhibitors (PPIs) in different doses for patients with duodenal ulcers. MATERIALS AND METHODS: An electronic database was searched to collect all randomized clinical trials (RCTs), and a pairwise and network meta-analysis were performed. RESULTS: A total of 24 RCTs involving 6188 patients were included. The network meta-analysis showed that there were no significant differences for the 4-week healing rate of duodenal ulcer treated with different PPI regimens except pantoprazle 40 mg/d versus lansoprazole 15 mg/d [Relative risk (RR) = 3.57; 95% confidence interval (CI) = 1.36-10.31)] and lansoprazole 30 mg/d versus lansoprazole 15 mg/d (RR = 2.45; 95% CI = 1.01-6.14). In comparison with H2receptor antagonists (H2RA), pantoprazole 40 mg/d and lansoprazole 30 mg/d significantly increase the healing rate (RR = 2.96; 95% CI = 1.78-5.14 and RR = 2.04; 95% CI = 1.13-3.53, respectively). There was no significant difference for the rate of adverse events between different regimens, including H2RA for a duration of 4-week of follow up. CONCLUSION: There was no significant difference for the efficacy and tolerance between the ordinary doses of different PPIs with the exception of lansoprazle 15 mg/d.
[Mh] Termos MeSH primário: Úlcera Duodenal/tratamento farmacológico
Inibidores da Bomba de Prótons/administração & dosagem
[Mh] Termos MeSH secundário: 2-Piridinilmetilsulfinilbenzimidazóis/administração & dosagem
2-Piridinilmetilsulfinilbenzimidazóis/uso terapêutico
Esquema de Medicação
Seres Humanos
Lansoprazol/administração & dosagem
Lansoprazol/uso terapêutico
Metanálise em Rede
Inibidores da Bomba de Prótons/uso terapêutico
Ensaios Clínicos Controlados Aleatórios como Assunto
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (2-Pyridinylmethylsulfinylbenzimidazoles); 0 (Proton Pump Inhibitors); 0K5C5T2QPG (Lansoprazole); D8TST4O562 (pantoprazole)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170201
[St] Status:MEDLINE
[do] DOI:10.4103/1319-3767.199117


  7 / 2000 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28083842
[Au] Autor:Takimoto M; Tomita T; Yamasaki T; Fukui S; Taki M; Okugawa T; Kondo T; Kono T; Tozawa K; Arai E; Ohda Y; Oshima T; Fukui H; Watari J; Miwa H
[Ad] Endereço:Division of Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, 1-1, Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan.
[Ti] Título:Effect of Vonoprazan, a Potassium-Competitive Acid Blocker, on the C-Urea Breath Test in Helicobacter pylori-Positive Patients.
[So] Source:Dig Dis Sci;62(3):739-745, 2017 Mar.
[Is] ISSN:1573-2568
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND AND AIM: Vonoprazan (VPZ) is a new oral potassium-competitive acid blocker that has recently become available. The aim of this study was to investigate the effects of VPZ on the urease activity of H. pylori as measured by the C-urea breath test ( C-UBT). PATIENTS AND METHODS: A total of 60 patients (26 men, 34 women; mean age 53.2 ± 13.6 years) who were diagnosed as H. pylori-positive were recruited. The patients were randomly allocated to three treatment groups: lansoprazole (LPZ) 30 mg (n = 20), VPZ 20 mg (n = 20) once daily for 3 weeks, or the control group (n = 20). The C-UBT was carried out at baseline and after 3 weeks of treatment, and the baseline and after treatment results then compared. Δ C‰ ≥ 2.5‰ was considered H. pylori-positive. RESULTS: Four patients failed to complete the medication and were omitted from the analysis; data from the LPZ group (n = 18), VPZ group (n = 18), and control group (n = 20) were analyzed. The control group showed no significant change in C-UBT data between baseline and the completion of 3-week treatment (baseline: 26.6 ± 23.0‰, completion: 21.1 ± 13.1‰). The C-UBT data at week 3 were significantly decreased in both the VPZ group (baseline: 32.8 ± 22.7‰, completion: 7.6 ± 9.2‰, p = 0.0002) and the LPZ group (baseline: 41.8 ± 33.4‰; completion: 9.6 ± 8.8‰, p = 0.0006) compared to baseline. CONCLUSIONS: VPZ treatment reduced the value of UBT, warning that UBT for patients with VPZ treatment should be evaluated carefully.
[Mh] Termos MeSH primário: Infecções por Helicobacter
Helicobacter pylori
Lansoprazol
Pirróis
Sulfonamidas
[Mh] Termos MeSH secundário: Adulto
Idoso
Testes Respiratórios/métodos
Monitoramento de Medicamentos/métodos
Feminino
Infecções por Helicobacter/diagnóstico
Infecções por Helicobacter/tratamento farmacológico
Infecções por Helicobacter/microbiologia
Helicobacter pylori/efeitos dos fármacos
Helicobacter pylori/enzimologia
Seres Humanos
Lansoprazol/administração & dosagem
Lansoprazol/efeitos adversos
Masculino
Meia-Idade
Inibidores da Bomba de Prótons/administração & dosagem
Inibidores da Bomba de Prótons/efeitos adversos
Pirróis/administração & dosagem
Pirróis/efeitos adversos
Sulfonamidas/administração & dosagem
Sulfonamidas/efeitos adversos
Resultado do Tratamento
Urease/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine); 0 (Proton Pump Inhibitors); 0 (Pyrroles); 0 (Sulfonamides); 0K5C5T2QPG (Lansoprazole); EC 3.5.1.5 (Urease)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:171019
[Lr] Data última revisão:
171019
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170114
[St] Status:MEDLINE
[do] DOI:10.1007/s10620-016-4439-0


  8 / 2000 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28039570
[Au] Autor:Costarelli L; Giacconi R; Malavolta M; Basso A; Piacenza F; Provinciali M; Maggio MG; Corsonello A; Lattanzio F
[Ad] Endereço:Translational Research Ctr. of Nutrition and Ageing, Scientific and Technological Pole, IRCCS-Italian National Research Center on Aging (INRCA), Via Birarelli 8, 60121, Ancona, Italy. l.costarelli@inrca.it.
[Ti] Título:Different transcriptional profiling between senescent and non-senescent human coronary artery endothelial cells (HCAECs) by Omeprazole and Lansoprazole treatment.
[So] Source:Biogerontology;18(2):217-236, 2017 Apr.
[Is] ISSN:1573-6768
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Recent evidence suggests that high dose and/or long term use of proton pump inhibitors (PPIs) may increase the risk of adverse cardiovascular events in older patients, but mechanisms underlying these detrimental effects are not known. Taking into account that the senescent endothelial cells have been implicated in the genesis or promotion of age-related cardiovascular disease, we hypothesized an active role of PPIs in senescent cells. The aim of this study is to investigate the changes in gene expression occurring in senescent and non-senescent human coronary artery endothelial cells (HCAECs) following Omeprazole (OPZ) or Lansoprazole (LPZ) treatment. Here, we show that atherogenic response is among the most regulated processes in PPI-treated HCAECs. PPIs induced down-regulation of anti-atherogenic chemokines (CXCL11, CXCL12 and CX3CL1) in senescent but not in non-senescent cells, while the same chemokines were up-regulated in untreated senescent cells. These findings support the hypothesis that up-regulated anti-atherogenic chemokines may represent a defensive mechanism against atherosclerosis during cellular senescence, and suggest that PPIs could activate pro-atherogenic pathways by changing the secretory phenotype of senescent HCAECs. Moreover, the genes coding for fatty acid binding protein 4 (FABP4) and piezo-type mechanosensitive ion channel component 2 (PIEZO2) were modulated by PPIs treatment with respect to untreated cells. In conclusions, our results show that long-term and high dose use of PPI could change the secretory phenotype of senescent cells, suggesting one of the potential mechanisms by which use of PPI can increase adverse outcomes in older subjects.
[Mh] Termos MeSH primário: Senescência Celular/fisiologia
Vasos Coronários/fisiologia
Células Endoteliais/fisiologia
Lansoprazol/administração & dosagem
Omeprazol/administração & dosagem
Transcriptoma/fisiologia
[Mh] Termos MeSH secundário: Células Cultivadas
Senescência Celular/efeitos dos fármacos
Vasos Coronários/citologia
Vasos Coronários/efeitos dos fármacos
Citocinas/metabolismo
Relação Dose-Resposta a Droga
Células Endoteliais/citologia
Células Endoteliais/efeitos dos fármacos
Regulação da Expressão Gênica no Desenvolvimento/efeitos dos fármacos
Regulação da Expressão Gênica no Desenvolvimento/fisiologia
Seres Humanos
Inibidores da Bomba de Prótons/administração & dosagem
Ativação Transcricional/efeitos dos fármacos
Ativação Transcricional/fisiologia
Transcriptoma/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cytokines); 0 (Proton Pump Inhibitors); 0K5C5T2QPG (Lansoprazole); KG60484QX9 (Omeprazole)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170101
[St] Status:MEDLINE
[do] DOI:10.1007/s10522-016-9675-3


  9 / 2000 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27891632
[Au] Autor:Miwa H; Uedo N; Watari J; Mori Y; Sakurai Y; Takanami Y; Nishimura A; Tatsumi T; Sakaki N
[Ad] Endereço:Hyogo College of Medicine, Hyogo, Japan.
[Ti] Título:Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers - results from two phase 3, non-inferiority randomised controlled trials.
[So] Source:Aliment Pharmacol Ther;45(2):240-252, 2017 Jan.
[Is] ISSN:1365-2036
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Vonoprazan is a new potassium-competitive acid blocker for treatment of acid-related diseases. AIM: To conduct two randomised-controlled trials, to evaluate the non-inferiority of vonoprazan vs. lansoprazole, a proton pump inhibitor, for treatment of gastric ulcer (GU) or duodenal ulcer (DU). METHODS: Patients aged ≥20 years with ≥1 endoscopically-confirmed GU or DU (≥5 mm white coating) were randomised 1:1 using double-dummy blinding to receive lansoprazole (30 mg) or vonoprazan (20 mg) for 8 (GU study) or 6 (DU study) weeks. The primary endpoint was the proportion of patients with endoscopically confirmed healed GU or DU. RESULTS: For GU, 93.5% (216/231) of vonoprazan-treated patients and 93.8% (211/225) of lansoprazole-treated patients achieved healed GU; non-inferiority of vonoprazan to lansoprazole was confirmed [difference = -0.3% (95% CI -4.750, 4.208); P = 0.0011]. For DU, 95.5% (170/178) of vonoprazan-treated patients and 98.3% (177/180) of lansoprazole-treated patients achieved healed DU; non-inferiority to lansoprazole was not confirmed [difference = -2.8% (95% CI -6.400, 0.745); P = 0.0654]. The incidences of treatment-emergent adverse events were slightly lower for GU and slightly higher for DU with vonoprazan than with lansoprazole. There was one death (subarachnoid haemorrhage) in the vonoprazan group (DU). The possibility of a relationship between this unexpected patient death and the study drug could not be ruled out. In both studies, increases in serum gastrin levels were greater in vonoprazan-treated vs. lansoprazole-treated patients; levels returned to baseline after treatment in both groups. CONCLUSIONS: Vonoprazan 20 mg has a similar tolerability profile to lansoprazole 30 mg and is non-inferior with respect to GU healing and has similar efficacy for DU healing.
[Mh] Termos MeSH primário: Antiulcerosos/uso terapêutico
Úlcera Duodenal/tratamento farmacológico
Lansoprazol/uso terapêutico
Inibidores da Bomba de Prótons/uso terapêutico
Pirróis/uso terapêutico
Úlcera Gástrica/tratamento farmacológico
Sulfonamidas/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Idoso
Antiulcerosos/efeitos adversos
Método Duplo-Cego
Úlcera Duodenal/diagnóstico
Endoscopia
Feminino
Seres Humanos
Lansoprazol/efeitos adversos
Masculino
Meia-Idade
Inibidores da Bomba de Prótons/efeitos adversos
Pirróis/efeitos adversos
Úlcera Gástrica/diagnóstico
Sulfonamidas/efeitos adversos
Resultado do Tratamento
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE III; JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine); 0 (Anti-Ulcer Agents); 0 (Proton Pump Inhibitors); 0 (Pyrroles); 0 (Sulfonamides); 0K5C5T2QPG (Lansoprazole)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170829
[Lr] Data última revisão:
170829
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161129
[St] Status:MEDLINE
[do] DOI:10.1111/apt.13876


  10 / 2000 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27639806
[Au] Autor:Tsai CF; Chen MH; Wang YP; Chu CJ; Huang YH; Lin HC; Hou MC; Lee FY; Su TP; Lu CL
[Ad] Endereço:Institute of Brain Science, National Yang-Ming University School of Medicine, Taipei, Taiwan; Faculty of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan; Department of Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan.
[Ti] Título:Proton Pump Inhibitors Increase Risk for Hepatic Encephalopathy in Patients With Cirrhosis in A Population Study.
[So] Source:Gastroenterology;152(1):134-141, 2017 Jan.
[Is] ISSN:1528-0012
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND & AIMS: Hepatic encephalopathy (HE) is a serious complication of cirrhosis and is associated with gut dysbiosis. Proton pump inhibitors (PPIs), frequently prescribed to patients with cirrhosis, can contribute to small-bowel bacterial overgrowth. We investigated whether PPI predisposes patients with cirrhosis to HE using a large database of patients. METHODS: We performed a case-control study nested within a sample of Taiwan National Health Insurance beneficiaries (n = 1,000,000), followed up longitudinally from 1998 through 2011. Patients with cirrhosis and an occurrence of HE (n = 1166) were selected as the case cohort and matched to patients without HE (1:1, controls) for sex, enrollment time, end point time, follow-up period, and advanced cirrhosis. Information on prescribed drugs, drug dosage, supply days, and numbers of dispensed pills was extracted from the Taiwan National Health Insurance database. PPI use was defined as more than 30 cumulative defined daily doses (cDDDs); PPI nonuse was defined as 30 cDDDs or fewer. We performed logistic regression analyses to estimate the association between PPI use and the occurrence of HE. RESULTS: Among patients with cirrhosis and an occurrence of HE, 38% (n = 445) had a history of PPI use before HE occurrence. We observed a relationship between dose of PPI taken and HE risk. The confounder-adjusted odd ratios were 1.41 (95% confidence interval [CI], 1.09-1.84), 1.51 (95% CI, 1.11-2.06), and 3.01 (95% CI, 1.78-5.10) for patients with 30-120 cDDDs, 120-365 cDDDs, and more than 365 cDDDs, respectively, compared with PPI nonusers. All categories of PPIs, except rabeprazole, were associated with an increased risk of HE. CONCLUSIONS: Based on an analysis of data from Taiwan National Health Insurance beneficiaries, we found that use of PPIs in patients with cirrhosis increases the risk for HE; risk increases with dose. It therefore is important for health care providers to carefully consider prolonged PPI use by patients with cirrhosis.
[Mh] Termos MeSH primário: Encefalopatia Hepática/epidemiologia
Encefalopatia Hepática/etiologia
Cirrose Hepática/complicações
Inibidores da Bomba de Prótons/administração & dosagem
[Mh] Termos MeSH secundário: 2-Piridinilmetilsulfinilbenzimidazóis/administração & dosagem
Demandas Administrativas em Assistência à Saúde/estatística & dados numéricos
Adulto
Idoso
Estudos de Casos e Controles
Esomeprazol/administração & dosagem
Feminino
Seres Humanos
Incidência
Seguro Saúde/estatística & dados numéricos
Lansoprazol/administração & dosagem
Estudos Longitudinais
Masculino
Meia-Idade
Omeprazol/administração & dosagem
Rabeprazol/administração & dosagem
Taiwan/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (2-Pyridinylmethylsulfinylbenzimidazoles); 0 (Proton Pump Inhibitors); 0K5C5T2QPG (Lansoprazole); 32828355LL (Rabeprazole); D8TST4O562 (pantoprazole); KG60484QX9 (Omeprazole); N3PA6559FT (Esomeprazole)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170613
[Lr] Data última revisão:
170613
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:160919
[St] Status:MEDLINE



página 1 de 200 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde